Findell Capital Management LLC Invests $3.02 Million in Vor Biopharma Inc. $VOR

Findell Capital Management LLC purchased a new position in shares of Vor Biopharma Inc. (NASDAQ:VOR) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 231,000 shares of the company’s stock, valued at approximately $3,021,000. Vor Biopharma accounts for 0.9% of Findell Capital Management LLC’s holdings, making the stock its 14th largest position.

Other hedge funds and other institutional investors have also modified their holdings of the company. Fcpm Iii Services B.V. purchased a new position in shares of Vor Biopharma during the third quarter worth $18,496,000. UBS Group AG boosted its position in shares of Vor Biopharma by 284.8% during the fourth quarter. UBS Group AG now owns 292,118 shares of the company’s stock worth $3,821,000 after buying an additional 216,209 shares during the period. NEXTBio Capital Management LP purchased a new position in shares of Vor Biopharma during the fourth quarter worth $13,080,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Vor Biopharma during the fourth quarter worth $33,275,000. Finally, Bollard Group LLC boosted its position in shares of Vor Biopharma by 763.8% during the fourth quarter. Bollard Group LLC now owns 23,987 shares of the company’s stock worth $314,000 after buying an additional 21,210 shares during the period. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock in a transaction on Monday, April 6th. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63. Following the completion of the transaction, the director directly owned 4,555,741 shares in the company, valued at approximately $75,579,743.19. This trade represents a 11.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 3,002,903 shares of company stock valued at $49,412,176 in the last ninety days. Company insiders own 0.27% of the company’s stock.

Vor Biopharma Trading Up 6.4%

NASDAQ:VOR opened at $15.02 on Thursday. The stock has a fifty day moving average price of $14.91 and a 200 day moving average price of $14.08. Vor Biopharma Inc. has a 12-month low of $4.06 and a 12-month high of $65.80.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that Vor Biopharma Inc. will post -2.51 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on VOR shares. Wedbush raised their price target on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Wall Street Zen lowered Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Weiss Ratings lowered Vor Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Finally, Wells Fargo & Company assumed coverage on Vor Biopharma in a report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Vor Biopharma currently has an average rating of “Moderate Buy” and a consensus target price of $42.25.

Vor Biopharma Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).